Clinical Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Rapid Antigen Tests During the Omicron Wave in South Africa( )

We evaluated the performance of nasal and nasopharyngeal Standard Q COVID-19 [coronavirus disease 2019] Ag tests (SD Biosensor) and the Panbio COVID-19 Ag Rapid Test Device (nasal; Abbott) against the Abbott RealTime severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay during the Omicr...

Descripción completa

Detalles Bibliográficos
Autores principales: Samsunder, Natasha, de Vos, Margaretha, Ngcapu, Sinaye, Giandhari, Jennifer, Lewis, Lara, Kharsany, Ayesha B M, Cawood, Cherie, de Oliveira, Tulio, Karim, Quarraisha Abdool, Karim, Salim Abdool, Naidoo, Kogieleum, Escadafal, Camille, Sivro, Aida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384653/
https://www.ncbi.nlm.nih.gov/pubmed/35921539
http://dx.doi.org/10.1093/infdis/jiac333
Descripción
Sumario:We evaluated the performance of nasal and nasopharyngeal Standard Q COVID-19 [coronavirus disease 2019] Ag tests (SD Biosensor) and the Panbio COVID-19 Ag Rapid Test Device (nasal; Abbott) against the Abbott RealTime severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay during the Omicron (clades 21M, 21K, and 21L) wave in South Africa. Overall, all evaluated tests performed well, with high sensitivity (range, 77.78%–81.42%) and excellent specificity values (>99%). The sensitivity of rapid antigen tests increased above 90% in samples with cycle threshold <20, and all 3 tests performed best within the first week after symptom onset.

Ejemplares similares